Broad-Spectrum Antibiotic and Prednisone for Community-Acquired Pneumonia
For hospitalized adults with community-acquired pneumonia (CAP), use a β-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) plus a macrolide (azithromycin) or respiratory fluoroquinolone (levofloxacin or moxifloxacin), and reserve prednisone 50 mg daily for 7 days only for patients with severe CAP requiring ICU admission.
Antibiotic Selection by Severity
Non-ICU Hospitalized Patients
For patients admitted to a medical ward without ICU-level illness, choose one of these regimens 1:
β-lactam plus macrolide (strong recommendation):
- Ceftriaxone 1-2 g IV daily OR cefotaxime 1 g IV every 8 hours
- PLUS azithromycin 500 mg IV/PO daily OR clarithromycin 500 mg PO twice daily
Respiratory fluoroquinolone monotherapy (strong recommendation):
- Levofloxacin 750 mg IV/PO daily OR moxifloxacin 400 mg IV/PO daily
For penicillin-allergic patients: Use respiratory fluoroquinolone alone 1.
ICU/Severe CAP Patients
For severe pneumonia requiring ICU admission, mandatory combination therapy includes 1:
- β-lactam (cefotaxime 1 g IV every 8 hours, ceftriaxone 1-2 g IV daily, or ampicillin-sulbactam 3 g IV every 6 hours)
- PLUS azithromycin 500 mg IV daily (level II evidence) OR respiratory fluoroquinolone (levofloxacin 750 mg IV daily) (level I evidence)
Special Populations Requiring Broader Coverage
If Pseudomonas risk factors present (structural lung disease, recent hospitalization, prior Pseudomonas isolation) 1:
- Antipseudomonal β-lactam (piperacillin-tazobactam 4.5 g IV every 6 hours, cefepime 2 g IV every 8 hours, imipenem, or meropenem)
- PLUS ciprofloxacin 400 mg IV every 8 hours OR levofloxacin 750 mg IV daily
- OR antipseudomonal β-lactam PLUS aminoglycoside PLUS azithromycin
If MRSA risk factors present (prior MRSA infection, IV drug use, recent influenza) 1:
- Add vancomycin 15-20 mg/kg IV every 8-12 hours OR linezolid 600 mg IV every 12 hours
Prednisone Use: Critical Decision Point
When to Use Prednisone
Prednisone 50 mg daily for 7 days should be used ONLY in severe CAP requiring ICU admission 2, 3. The 2015 Swiss trial demonstrated that prednisone reduces time to clinical stability (3.0 vs 4.4 days, p<0.0001) and shortens hospital length of stay without increasing complications in hospitalized CAP patients 2.
However, more recent evidence from the 2024 REMAP-CAP trial and updated 2025 ATS guidelines suggest corticosteroids may only benefit a very small subset of patients with severe CAP and high inflammatory markers (CRP >150 mg/L) 4, 5, 6.
When NOT to Use Prednisone
Do not use corticosteroids in 7, 4, 5:
- Non-severe CAP (outpatient or non-ICU hospitalized patients)
- Viral pneumonia (except hypoxemic COVID-19)
- Patients without significantly elevated inflammatory markers
Key caveat: A 2010 trial showed that prednisolone 40 mg daily did NOT improve clinical cure rates and was associated with increased late failure (>72 hours) in hospitalized CAP patients 7. The conflicting evidence suggests corticosteroids should be reserved for the sickest patients only.
Prednisone Dosing When Indicated
If using corticosteroids in severe CAP 2, 8:
- Prednisone 50 mg PO/IV daily for 7 days
- Alternative: Hydrocortisone 200 mg/day divided doses
- Start within 36 hours of admission
- Monitor for hyperglycemia (19% vs 11% incidence) requiring insulin 2
Duration of Antibiotic Therapy
Treat for minimum 5 days if patient meets ALL criteria 1:
- Afebrile for 48-72 hours
- Hemodynamically stable
- Able to take oral medications
- No more than 1 sign of clinical instability
Extend to 7-10 days for standard cases 1, 9.
Extend to 14-21 days if Legionella, Staphylococcus aureus, or gram-negative bacilli confirmed 10.
Common Pitfalls to Avoid
- Do not use macrolide monotherapy in hospitalized patients—resistance rates make this inadequate 1
- Do not routinely use corticosteroids in non-severe CAP—no mortality benefit and increased complications 7, 4
- Do not delay antibiotics while awaiting diagnostic testing—administer in ED immediately 1
- Do not continue IV antibiotics once patient is stable and tolerating oral intake—switch to oral within 2-3 days 1
- Do not use fluoroquinolones if patient received them in past 3 months—select alternative regimen 11